L. Sanz

发表

Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen

Jeremy N. Burrows, Benigno Crespo, Francisco-Javier Gamo, 2011, Antimicrobial Agents and Chemotherapy.

Thousands of chemical starting points for antimalarial lead identification

James R. Brown, L. Cardon, C. E. Peishoff, 2010, Nature.

Quinolone-3-Diarylethers: A New Class of Antimalarial Drug

Yuexin Li, David M. Shackleford, Susan A Charman, 2013, Science Translational Medicine.

High-throughput microsphiltration to assess red blood cell deformability and screen for malaria transmission–blocking drugs

F. Gamo, Laura M Sanz, P. Buffet, 2018, Nature Protocols.

A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue

Patrick G. Schupp, J. Derisi, J. Gut, 2017, Nature Communications.

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

David M. Shackleford, G. Drewes, M. Bantscheff, 2017, Science Translational Medicine.

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance

R. Price, P. Rosenthal, D. Fidock, 2021, Science Translational Medicine.

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

David M. Shackleford, R. Price, D. Fidock, 2017, Nature Communications.

A novel multiple-stage antimalarial agent that inhibits protein synthesis

David W. Gray, E. Winzeler, S. Meister, 2015, Nature.

Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans

N. A. Malmquist, R. Sinden, F. Gamo, 2014, Antimicrobial Agents and Chemotherapy.

Quinolone-3-Diarylethers : A new class of drugs for a new era of malaria eradication

David M. Shackleford, R. Price, M. Mather, 2014 .

Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.

Laura M Sanz, L. Ballell-Pages, M. Blackman, 2015, Journal of Medicinal Chemistry.

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

P. Rosenthal, M. Llinás, D. Fidock, 2021, bioRxiv.

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Juan A. Bueren-Calabuig, Andrei V. Pisliakov, David W. Gray, 2019, Proceedings of the National Academy of Sciences.

A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission

S. Croft, T. Bousema, F. Gamo, 2017, Nature Communications.

Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.

V. Ciaravino, P. Rosenthal, F. Gamo, 2017, Journal of medicinal chemistry.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

R. Price, D. Fidock, R. Sinden, 2016, PLoS medicine.

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials

E. Winzeler, S. Meister, S. Norval, 2016, Journal of medicinal chemistry.

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate

D. Wirth, D. Fidock, Pavithra Viswanath, 2015, Nature Communications.

N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.

D. Fidock, F. Gamo, A. Srivastava, 2014, Journal of medicinal chemistry.

Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.

D. Wirth, F. Gamo, Pavithra Viswanath, 2014, Journal of medicinal chemistry.

Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS).

Simon J F Macdonald, F. Gamo, Laura M Sanz, 2011, ACS medicinal chemistry letters.

Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance

M. Foley, P. Rosenthal, P. Bhanot, 2018, Proceedings of the National Academy of Sciences.

Identification and Activity of a Series of Azole-based Compounds with Lactate Dehydrogenase-directed Anti-malarial Activity*

Araceli, V. J. Winter, S. Croft, 2004, Journal of Biological Chemistry.

Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine

P. Wilairat, F. Gamo, N. White, 2018, International journal for parasitology. Drugs and drug resistance.

Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing N-Methyl Amino Acids as Antiplasmodial Agents.

E. Winzeler, V. Yardley, F. Gamo, 2018, ACS medicinal chemistry letters.

Magnetic isolation of Plasmodium falciparum schizonts iRBCs to generate a high parasitaemia and synchronized in vitro culture

M. Lafuente, M. Rodriguez, Lydia Mata-Cantero, 2014, Malaria Journal.

Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay

F. Gamo, Virginia Franco, Benigno Crespo, 2015, Malaria Journal.

Benzoxaborole Antimalarial Agents. Part 4. Discovery of Potent 6-(2-(Alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles

P. Rosenthal, F. Gamo, J. Plattner, 2015, Journal of medicinal chemistry.

P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action

Jeremy N. Burrows, Benigno Crespo, Francisco-Javier Gamo, 2012, PloS one.

Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.

David M. Shackleford, Laura M Sanz, K. Dechering, 2021, Journal of medicinal chemistry.

Safe drugs with high potential to block malaria transmission revealed by a spleen-mimetic screening

Pablo Gamallo, F. Gamo, J. Tarning, 2023, Nature Communications.

Development of a Novel High-Density [3H]Hypoxanthine Scintillation Proximity Assay To Assess Plasmodium falciparum Growth

F. Gamo, Gonzalo Colmenarejo, E. Álvarez-Ruíz, 2016, Antimicrobial Agents and Chemotherapy.

A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.

Laura M Sanz, L. Ballell-Pages, J. Yli-Kauhaluoma, 2015, Journal of medicinal chemistry.

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

E. Winzeler, S. Meister, J. Rayner, 2016, Nature.

Lumefantrine attenuates Plasmodium falciparum artemisinin resistance during the early ring stage

P. Wilairat, F. Gamo, Laura M Sanz, 2021, International journal for parasitology. Drugs and drug resistance.

Evaluation of 4-Amino 2-Anilinoquinazolines against Plasmodium and Other Apicomplexan Parasites In Vitro and in a P. falciparum Humanized NOD-scid IL2Rγnull Mouse Model of Malaria

Christopher J. Tonkin, A. Cowman, F. Gamo, 2018, Antimicrobial Agents and Chemotherapy.

Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors

David M. Shackleford, D. Fidock, Laura M Sanz, 2021, ACS infectious diseases.

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity.

Danny W. Wilson, G. McFadden, A. Cowman, 2021, Bioorganic chemistry.